Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis
| Autor: | Tomoyuki Imagawa, Kenji Waki, Yuri Etani, Shoko Nakashima, Ayano Inui, Shumpei Yokota, Tomoo Fujisawa, Hitoshi Tajiri, Yukitoshi Shimizu, Haruki Komatsu, Tsuyoshi Sogo |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Hepatology Growth retardation Intravenous methylprednisolone business.industry Pulse therapy Azathioprine Autoimmune hepatitis medicine.disease Gastroenterology Infectious Diseases Endocrinology Prednisone Internal medicine Induction therapy medicine business Body mass index medicine.drug |
| Zdroj: | Hepatology Research. 34:187-192 |
| ISSN: | 1386-6346 |
| DOI: | 10.1016/j.hepres.2005.12.002 |
| Popis: | Objective To estimate an efficacy of intravenous methylprednisolone pulse therapy (m-PSL) and the occurrence of corticosteroid-related side effects in children with autoimmune hepatitis (AIH), compared with oral corticosteroid therapy. Study design The subjects consisted of nine children with AIH. Patients were divided into two groups. Group 1 was consisted of four patients who were treated with conventional oral prednisone therapy without m-PSL. Group 2 was consisted of five children who were treated with m-PSL as an induction therapy and maintained on oral prednisone. Results The median duration needed for normalization of alanine aminotransferase was 285 days (range 18–617 days) in group 1 and 54 days (range 15–116 days) in group 2. The most frequent side effects were obesity and growth retardation. The Z -score in group 1 tended to be lower than in group 2 and body mass index in group 1 tended to be higher than in group 2. Conclusion The m-PSL may become a safe and effective therapy for children with AIH. Further study is needed to establish the appropriate therapy for AIH in children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|